The global pancreatic and bile duct cancer drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Some major factors that are anticipated to drive the market growth include the rising prevalence of pancreatic cancer and cholangiocarcinoma. Pancreatic and bile duct cancer drugs are of different types. Some drugs treat cancer, whereas, others support relieving symptoms such as sickness and pain. 5-fluorouracil, gemcitabine, cisplatin, capecitabine, oxaliplatin are the commonly used drugs for bile duct cancer. Abraxane, Afinitor, erlotinib hydrochloride, everolimus, and 5-FU are among the approved drugs for pancreatic cancer.
A full report of Pancreatic and Bile Duct Cancer Drug Market is available at: https://www.omrglobal.com/industry-reports/pancreatic-and-bile-duct-cancer-drug-market
The rise in pancreatic cancer patients across the globe due to factors such as age, smoking, diabetes and family history, also drive demand for pancreatic and bile duct cancer drugs. The global pancreatic and bile duct cancer drug market analysis includes some of the key market players such as 3-V Biosciences Inc., 4P-Pharma SAS, 4SC AG, AB Science SA, AbbVie Inc., AbGenomics International Inc., and Ability Pharmaceuticals SL, among others. To maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. Further, in December 2021, scientists at Washington University School of Medicine in St. Louis have discovered a drug combination that renders pancreatic cancer cells more vulnerable to chemotherapy. FOLFIRINOX is the first-line treatment for pancreatic cancer, however, only around one out of every three patients will see their tumor shrink. The researchers plan to continue exploring ATI-450 for pancreatic cancer, particularly if this medicine in combination with other investigational treatments, such as immunotherapies, can be effective.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/pancreatic-and-bile-duct-cancer-drug-market
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
- Competitive Landscape: 3-V Biosciences Inc., 4P-Pharma SAS, 4SC AG, AB Science SA, AbbVie Inc., AbGenomics International Inc., and Ability Pharmaceuticals SL, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Pancreatic and Bile Duct Cancer Drug Market Report Segmentation
By Product Type
• Vascular Endothelial Growth Factor Receptors
• Programmed Cell Death Protein 1
• Others
By Application
• Pancreatic Cancer
• Cholangiocarcinoma
